Does the media favor AVTX or CAMP?

In the previous week, CAMP4 Therapeutics had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 6 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.74 beat CAMP4 Therapeutics' score of 0.72 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CAMP4 Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CAMP or CVAC?

CAMP4 Therapeutics currently has a consensus price target of $9.56, suggesting a potential upside of 151.64%. Given CAMP4 Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe CAMP4 Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CAMP4 Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor SLDB or CAMP?

In the previous week, CAMP4 Therapeutics had 7 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 2 mentions for Solid Biosciences. CAMP4 Therapeutics' average media sentiment score of 0.72 beat Solid Biosciences' score of 0.56 indicating that CAMP4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CAMP4 Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CAMP or CADL?

In the previous week, CAMP4 Therapeutics had 6 more articles in the media than Candel Therapeutics. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 3 mentions for Candel Therapeutics. CAMP4 Therapeutics' average media sentiment score of 0.72 beat Candel Therapeutics' score of 0.60 indicating that CAMP4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CAMP4 Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CAMP or ABUS?

In the previous week, CAMP4 Therapeutics had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 5 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.67 beat CAMP4 Therapeutics' score of 0.72 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CAMP4 Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arbutus Biopharma 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

CAMP4 Therapeutics (CAMP) Competitors

$3.92 +0.12 (+3.11%)

As of 09:47 AM Eastern

Compare

CAMP vs. AVTX, CVAC, SLDB, CADL, and ABUS

Should you buy CAMP4 Therapeutics stock or one of its competitors? CAMP4 Therapeutics's main competitors and comparable companies include Avalo Therapeutics (AVTX), CureVac (CVAC), Solid Biosciences (SLDB), Candel Therapeutics (CADL), and Arbutus Biopharma (ABUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CAMP4 Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

87.1% of Avalo Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Avalo Therapeutics has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Avalo Therapeutics' return on equity of -58.03% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

Avalo Therapeutics presently has a consensus price target of $45.10, indicating a potential upside of 133.20%. CAMP4 Therapeutics has a consensus price target of $9.56, indicating a potential upside of 151.64%. Given CAMP4 Therapeutics' higher probable upside, analysts plainly believe CAMP4 Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Avalo Therapeutics has higher earnings, but lower revenue than CAMP4 Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$59K	17,579.73	-$78.26M	-$4.37	N/A
CAMP4 Therapeutics	$3.50M	68.13	-$80.40M	-$2.32	N/A

In the previous week, CAMP4 Therapeutics had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 6 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.74 beat CAMP4 Therapeutics' score of 0.72 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CAMP4 Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Summary

Avalo Therapeutics beats CAMP4 Therapeutics on 10 of the 16 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to CureVac?

CAMP4 Therapeutics (NASDAQ:CAMP) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

17.3% of CureVac shares are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to CAMP4 Therapeutics' net margin of -2,543.74%. CureVac's return on equity of -23.03% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%
CureVac	199.92%	-23.03%	-19.09%

CureVac has higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50M	68.13	-$80.40M	-$2.32	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CAMP4 Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

In the previous week, CAMP4 Therapeutics had 9 more articles in the media than CureVac. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 0 mentions for CureVac. CAMP4 Therapeutics' average media sentiment score of 0.72 beat CureVac's score of 0.00 indicating that CAMP4 Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CAMP4 Therapeutics	Positive
CureVac	Neutral

CAMP4 Therapeutics currently has a consensus price target of $9.56, suggesting a potential upside of 151.64%. Given CAMP4 Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe CAMP4 Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CureVac beats CAMP4 Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

CAMP4 Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
CAMP4 Therapeutics	$3.50M	68.13	-$80.40M	-$2.32	N/A

Solid Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Solid Biosciences currently has a consensus price target of $18.18, suggesting a potential upside of 76.87%. CAMP4 Therapeutics has a consensus price target of $9.56, suggesting a potential upside of 151.64%. Given CAMP4 Therapeutics' higher probable upside, analysts clearly believe CAMP4 Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

81.5% of Solid Biosciences shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Solid Biosciences has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Solid Biosciences' return on equity of -71.35% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

In the previous week, CAMP4 Therapeutics had 7 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 2 mentions for Solid Biosciences. CAMP4 Therapeutics' average media sentiment score of 0.72 beat Solid Biosciences' score of 0.56 indicating that CAMP4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CAMP4 Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solid Biosciences beats CAMP4 Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Candel Therapeutics?

CAMP4 Therapeutics (NASDAQ:CAMP) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, CAMP4 Therapeutics had 6 more articles in the media than Candel Therapeutics. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 3 mentions for Candel Therapeutics. CAMP4 Therapeutics' average media sentiment score of 0.72 beat Candel Therapeutics' score of 0.60 indicating that CAMP4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CAMP4 Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CAMP4 Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.48, suggesting that its share price is 148% less volatile than the broader market.

Candel Therapeutics has lower revenue, but higher earnings than CAMP4 Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50M	68.13	-$80.40M	-$2.32	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

Candel Therapeutics has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Candel Therapeutics' return on equity of -76.98% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%
Candel Therapeutics	N/A	-76.98%	-48.50%

CAMP4 Therapeutics presently has a consensus price target of $9.56, suggesting a potential upside of 151.64%. Candel Therapeutics has a consensus price target of $19.29, suggesting a potential upside of 46.10%. Given CAMP4 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CAMP4 Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

13.9% of Candel Therapeutics shares are owned by institutional investors. 21.7% of CAMP4 Therapeutics shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CAMP4 Therapeutics beats Candel Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Arbutus Biopharma?

CAMP4 Therapeutics (NASDAQ:CAMP) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

CAMP4 Therapeutics currently has a consensus target price of $9.56, indicating a potential upside of 151.64%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential downside of 1.96%. Given CAMP4 Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe CAMP4 Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

CAMP4 Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Arbutus Biopharma has higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50M	68.13	-$80.40M	-$2.32	N/A
Arbutus Biopharma	$14.08M	71.76	-$33.50M	$0.79	6.46

Arbutus Biopharma has a net margin of 84.22% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Arbutus Biopharma's return on equity of 90.98% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%
Arbutus Biopharma	84.22%	90.98%	82.34%

In the previous week, CAMP4 Therapeutics had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 5 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.67 beat CAMP4 Therapeutics' score of 0.72 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CAMP4 Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arbutus Biopharma	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

43.8% of Arbutus Biopharma shares are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Arbutus Biopharma beats CAMP4 Therapeutics on 11 of the 16 factors compared between the two stocks.

Get CAMP4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAMP vs. The Competition

Export

Metric	CAMP4 Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$237.84M	$3.99B	$7.21B	$12.66B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-1.64	12.25	272.68	25.23
Price / Sales	68.13	1,387.15	630.59	104.23
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	-380.00	16.58	12.99	6.10
Net Income	-$80.40M	-$22.72M	$3.47B	$348.86M
7 Day Performance	-8.21%	-1.24%	-0.10%	-1.90%
1 Month Performance	-9.74%	11.25%	6.76%	1.96%
1 Year Performance	165.73%	53.08%	25.09%	15.30%

CAMP4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAMP CAMP4 Therapeutics	3.8314 of 5 stars	$3.92 +3.1%	$9.56 +144.1%	+147.4%	$247.11M	$3.50M	N/A	644	Insider Trade
AVTX Avalo Therapeutics	3.0072 of 5 stars	$19.64 -0.5%	$45.10 +129.7%	+114.4%	$1.05B	$60K	N/A	40	News Coverage
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
SLDB Solid Biosciences	1.9457 of 5 stars	$9.70 -1.9%	$17.40 +79.3%	+89.3%	$1.04B	N/A	N/A	100	Gap Up
CADL Candel Therapeutics	2.7546 of 5 stars	$13.54 -0.5%	$19.29 +42.5%	+125.3%	$1.04B	N/A	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAMP) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CAMP4 Therapeutics (CAMP) Competitors

CAMP vs. AVTX, CVAC, SLDB, CADL, and ABUS

How does CAMP4 Therapeutics compare to Avalo Therapeutics?

Summary

How does CAMP4 Therapeutics compare to CureVac?

Summary

How does CAMP4 Therapeutics compare to Solid Biosciences?

Summary

How does CAMP4 Therapeutics compare to Candel Therapeutics?

Summary

How does CAMP4 Therapeutics compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAMP vs. The Competition

CAMP4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CAMP4 Therapeutics (CAMP) Competitors

CAMP vs. AVTX, CVAC, SLDB, CADL, and ABUS

How does CAMP4 Therapeutics compare to Avalo Therapeutics?

Do insiders and institutionals believe in AVTX or CAMP?

Is AVTX or CAMP more profitable?

Do analysts prefer AVTX or CAMP?

Which has stronger valuation and earnings, AVTX or CAMP?

Does the media favor AVTX or CAMP?

Which has more volatility & risk, AVTX or CAMP?

Summary

How does CAMP4 Therapeutics compare to CureVac?

Do insiders and institutionals hold more shares of CAMP or CVAC?

Is CAMP or CVAC more profitable?

Which has stronger earnings and valuation, CAMP or CVAC?

Which has more volatility & risk, CAMP or CVAC?

Does the media favor CAMP or CVAC?

Do analysts recommend CAMP or CVAC?

Summary

How does CAMP4 Therapeutics compare to Solid Biosciences?

Which has higher valuation & earnings, SLDB or CAMP?

Which has more volatility & risk, SLDB or CAMP?

Do analysts prefer SLDB or CAMP?

Do insiders and institutionals hold more shares of SLDB or CAMP?

Is SLDB or CAMP more profitable?

Does the media favor SLDB or CAMP?

Summary

How does CAMP4 Therapeutics compare to Candel Therapeutics?

Does the media prefer CAMP or CADL?

Which has more volatility & risk, CAMP or CADL?

Which has better valuation & earnings, CAMP or CADL?

Is CAMP or CADL more profitable?

Do analysts recommend CAMP or CADL?

Do insiders & institutionals have more ownership in CAMP or CADL?

Summary

How does CAMP4 Therapeutics compare to Arbutus Biopharma?

Do analysts rate CAMP or ABUS?

Which has more volatility & risk, CAMP or ABUS?

Which has stronger valuation & earnings, CAMP or ABUS?

Is CAMP or ABUS more profitable?

Does the media refer more to CAMP or ABUS?

Do institutionals and insiders believe in CAMP or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAMP vs. The Competition

CAMP4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools